S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NASDAQ:RTRX

Travere Therapeutics News Headlines

Notice: This company has been marked as potentially delisted and may not be actively trading.
$26.99
+0.65 (+2.47 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.50
Now: $26.99
$28.43
50-Day Range
$24.25
MA: $26.56
$28.18
52-Week Range
$8.98
Now: $26.99
$24.96
Volume736,469 shs
Average Volume412,277 shs
Market Capitalization$1.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.67

Headlines

Travere Therapeutics (NASDAQ RTRX) News Headlines Today

Source:
SourceHeadline
Travere Therapeutics IncTravere Therapeutics Inc
reuters.com - March 5 at 5:18 PM
Travere Therapeutics concludes enrollment in late-stage study of sparsentan in rare kidney disorderTravere Therapeutics concludes enrollment in late-stage study of sparsentan in rare kidney disorder
seekingalpha.com - December 1 at 8:33 AM
Retrophin rebrands itself as Travere TherapeuticsRetrophin rebrands itself as Travere Therapeutics
seekingalpha.com - November 17 at 2:31 PM
Retrophin, Founded by Martin Shkreli, Rebrands Itself as Travere Therapeutics - The Wall Street JournalRetrophin, Founded by Martin Shkreli, Rebrands Itself as Travere Therapeutics - The Wall Street Journal
wsj.com - November 16 at 8:24 AM
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
finance.yahoo.com - November 16 at 8:24 AM
Retrophin Completes Acquisition of Orphan Technologies Nasdaq:RTRX - GlobeNewswireRetrophin Completes Acquisition of Orphan Technologies Nasdaq:RTRX - GlobeNewswire
globenewswire.com - November 12 at 6:31 PM
Retrophin Completes Acquisition of Orphan TechnologiesRetrophin Completes Acquisition of Orphan Technologies
finance.yahoo.com - November 12 at 6:31 PM
Regeneron Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year - NasdaqRegeneron Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year - Nasdaq
nasdaq.com - November 9 at 8:15 PM
Retrophin, Inc. (NASDAQ:RTRX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$33.33 - Yahoo FinanceRetrophin, Inc. (NASDAQ:RTRX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$33.33 - Yahoo Finance
finance.yahoo.com - November 9 at 3:14 PM
Retrophin, Inc. (NASDAQ:RTRX) Just Reported And Analysts Have Been Lifting Their Price TargetsRetrophin, Inc. (NASDAQ:RTRX) Just Reported And Analysts Have Been Lifting Their Price Targets
nasdaq.com - November 9 at 9:56 AM
Retrophin, Inc. (NASDAQ:RTRX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$33.33Retrophin, Inc. (NASDAQ:RTRX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$33.33
finance.yahoo.com - November 9 at 9:56 AM
Retrophins (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call Transcript - Seeking AlphaRetrophin's (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 12:58 PM
Retrophin EPS beats by $0.07, beats on revenueRetrophin EPS beats by $0.07, beats on revenue
seekingalpha.com - November 6 at 12:23 PM
Retrophin: 3Q Earnings Snapshot - Yahoo FinanceRetrophin: 3Q Earnings Snapshot - Yahoo Finance
finance.yahoo.com - November 6 at 1:26 AM
Retrophin (RTRX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance AustraliaRetrophin (RTRX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance Australia
finance.yahoo.com - November 5 at 8:26 PM
Retrophin Reports Third Quarter 2020 Financial Results Nasdaq:RTRX - GlobeNewswireRetrophin Reports Third Quarter 2020 Financial Results Nasdaq:RTRX - GlobeNewswire
globenewswire.com - November 5 at 8:26 PM
Retrophin Reports Third Quarter 2020 Financial ResultsRetrophin Reports Third Quarter 2020 Financial Results
finance.yahoo.com - November 5 at 8:26 PM
Retrophin (RTRX) Reports Q3 Loss, Tops Revenue EstimatesRetrophin (RTRX) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 5 at 8:26 PM
Retrophin, Inc. to Host Earnings CallRetrophin, Inc. to Host Earnings Call
finance.yahoo.com - November 5 at 3:25 PM
Retrophin (RTRX) Expected to Beat Earnings Estimates: Should You Buy? - NasdaqRetrophin (RTRX) Expected to Beat Earnings Estimates: Should You Buy? - Nasdaq
nasdaq.com - October 29 at 5:55 PM
Retrophin (RTRX) Expected to Beat Earnings Estimates: Should You Buy?Retrophin (RTRX) Expected to Beat Earnings Estimates: Should You Buy?
finance.yahoo.com - October 29 at 5:55 PM
Retrophin (RTRX) to Acquire Orphan Technologies - StreetInsider.comRetrophin (RTRX) to Acquire Orphan Technologies - StreetInsider.com
streetinsider.com - October 23 at 6:02 PM
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebias Positive Readout, Foghorn IPO - BenzingaThe Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO - Benzinga
benzinga.com - October 23 at 7:44 AM
Retrophin Announces Agreement to Acquire Orphan Technologies - GlobeNewswireRetrophin Announces Agreement to Acquire Orphan Technologies - GlobeNewswire
globenewswire.com - October 22 at 7:55 PM
Retrophin to Report Third Quarter 2020 Financial Results - GlobeNewswireRetrophin to Report Third Quarter 2020 Financial Results - GlobeNewswire
globenewswire.com - October 21 at 6:02 PM
Retrophin to Report Third Quarter 2020 Financial ResultsRetrophin to Report Third Quarter 2020 Financial Results
finance.yahoo.com - October 21 at 6:02 PM
NephCure Kidney International, Retrophin, AAKP Release Call to Action for Revolutionizing Rare Kidney Disease Diagnosis, Treatment, and Education - Yahoo FinanceNephCure Kidney International, Retrophin, AAKP Release Call to Action for Revolutionizing Rare Kidney Disease Diagnosis, Treatment, and Education - Yahoo Finance
finance.yahoo.com - October 21 at 1:01 PM
Retrophin Inc. Registered Share (17R.SG)Retrophin Inc. Registered Share (17R.SG)
au.finance.yahoo.com - October 11 at 9:48 PM
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined - GlobeNewswireRetrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined - GlobeNewswire
globenewswire.com - October 9 at 6:20 PM
Hedge Funds Have Never Been This Bullish On Retrophin Inc (RTRX)Hedge Funds Have Never Been This Bullish On Retrophin Inc (RTRX)
finance.yahoo.com - October 7 at 5:23 PM
Hedge Funds Have Never Been This Bullish On Retrophin Inc (RTRX) - Yahoo FinanceHedge Funds Have Never Been This Bullish On Retrophin Inc (RTRX) - Yahoo Finance
finance.yahoo.com - September 29 at 1:00 AM
Retrophin enrolls patients for the study of sparsentan in IgA nephropathyRetrophin enrolls patients for the study of sparsentan in IgA nephropathy
seekingalpha.com - September 21 at 7:58 PM
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy - GlobeNewswireRetrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy - GlobeNewswire
globenewswire.com - September 21 at 9:56 AM
2020 NORD Summit to Feature Leading Experts in Public Policy, Patient Advocacy, Rare Disease Research and Regulatory Science - Yahoo Finance2020 NORD Summit to Feature Leading Experts in Public Policy, Patient Advocacy, Rare Disease Research and Regulatory Science - Yahoo Finance
finance.yahoo.com - September 10 at 11:18 PM
2020 NORD Summit to Feature Leading Experts in Public Policy, Patient Advocacy, Rare Disease Research and Regulatory Science - StreetInsider.com2020 NORD Summit to Feature Leading Experts in Public Policy, Patient Advocacy, Rare Disease Research and Regulatory Science - StreetInsider.com
streetinsider.com - September 10 at 1:13 PM
Retrophin Inc.Retrophin Inc.
marketwatch.com - September 5 at 7:47 PM
Is Retrophin (NASDAQ:RTRX) Using Debt In A Risky Way?Is Retrophin (NASDAQ:RTRX) Using Debt In A Risky Way?
finance.yahoo.com - August 28 at 3:30 PM
Benzingas Top Upgrades, Downgrades For August 24, 2020 - Yahoo FinanceBenzinga's Top Upgrades, Downgrades For August 24, 2020 - Yahoo Finance
finance.yahoo.com - August 24 at 5:45 PM
BofA bullish on Retrophin, sees 56% upside - Seeking AlphaBofA bullish on Retrophin, sees 56% upside - Seeking Alpha
seekingalpha.com - August 24 at 5:45 PM
Benzingas Top Upgrades, Downgrades For August 24, 2020 - BenzingaBenzinga's Top Upgrades, Downgrades For August 24, 2020 - Benzinga
benzinga.com - August 24 at 12:44 PM
Benzinga's Top Upgrades, Downgrades For August 24, 2020Benzinga's Top Upgrades, Downgrades For August 24, 2020
finance.yahoo.com - August 24 at 12:44 PM
Retrophin, Inc. (RTRX) CEO Eric Dube on Q2 2020 Results - Earnings Call Transcript - Seeking AlphaRetrophin, Inc. (RTRX) CEO Eric Dube on Q2 2020 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 3 at 12:19 AM
Edited Transcript of RTRX.OQ earnings conference call or presentation 30-Jul-20 8:30pm GMT - Yahoo FinanceEdited Transcript of RTRX.OQ earnings conference call or presentation 30-Jul-20 8:30pm GMT - Yahoo Finance
finance.yahoo.com - July 31 at 8:43 PM
Retrophin EPS beats by $0.14, beats on revenueRetrophin EPS beats by $0.14, beats on revenue
seekingalpha.com - July 31 at 3:42 PM
Retrophin (RTRX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo FinanceRetrophin (RTRX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
finance.yahoo.com - July 30 at 11:31 PM
Retrophin (RTRX) Reports Q2 Loss, Misses Revenue EstimatesRetrophin (RTRX) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - July 30 at 11:30 PM
Retrophin Reports Second Quarter 2020 Financial Results Nasdaq:RTRX - GlobeNewswireRetrophin Reports Second Quarter 2020 Financial Results Nasdaq:RTRX - GlobeNewswire
www.globenewswire.com - July 30 at 6:30 PM
Retrophin Reports Second Quarter 2020 Financial ResultsRetrophin Reports Second Quarter 2020 Financial Results
finance.yahoo.com - July 30 at 6:30 PM
Code and Theory accelerates innovation with creation of Code and Theory Health and the addition of Rare Disease leader Scout Health - Yahoo FinanceCode and Theory accelerates innovation with creation of Code and Theory Health and the addition of Rare Disease leader Scout Health - Yahoo Finance
finance.yahoo.com - July 29 at 2:29 PM
Retrophin (RTRX) May Report Negative Earnings: Know the Trend Ahead of Next Weeks Release - Yahoo FinanceRetrophin (RTRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
finance.yahoo.com - July 23 at 3:33 PM
This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.